




Pioneers of Restorative Therapeutics


Synaptogenix is a clinical-stage biopharmaceutical company discovering restorative, novel therapeutics for patients with life-altering neurodegenerative diseases and developmental disorders. Synaptogenix is currently conducting a National Institutes of Health (NIH) sponsored Phase 2b clinical trial of its lead therapeutic candidate Bryostatin-1 in patients suffering from moderate to severe Alzheimer's disease (AD). In addition to AD, preclinical studies have demonstrated Bryostatin-1's regenerative mechanisms of action for the rare disease Fragile X syndrome, and the U.S. Food and Drug Administration has granted the drug Orphan Drug Designation for this indication. Other potential indications include multiple sclerosis (MS), stroke, traumatic brain injury, and autism spectrum disorders. Bryostatin has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs.

Key Investment Considerations

- Technology developed over a decade through funding of \$200M+ by Blanchette Rockefeller Neurosciences Institute and the National Institutes of Health (NIH).
• Successful translation of decades of pre-clinical work to the clinic; Phase 2b clinical trial underway for Bryostatin-1 as a treatment for Alzheimer's disease.
• Massive market opportunity in Alzheimer's disease treatment; according to the Alzheimer's Association, AD treatment and care cost the U.S. government over \$305 billion in 2020.
• Potential as treatment for additional central nervous system disorders including Fragile X syndrome, multiple sclerosis (MS), autism, Parkinson's disease, traumatic brain injury, and stroke.
• Clean capital structure and strong cash position of \$31M; six years of operating runway.
• Leadership with deep expertise in neurodegenerative disorders and successful track records in both drug discovery and development; 30+ years of experience with the development of bryostatin and other platform drugs.



Bryostatin-1 Development Pipeline



2022 Recent News

- Synaptogenix Announces Publication of Peer-Reviewed Scientific Manuscript Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients


Synaptic loss is the major pathologic correlate of Alzheimer's disease and other dementias, and has been shown to occur in very early stages of such diseases.²

Bryostatin: Promotes Neuronal Health and Synaptic Regeneration

Bryostatin is a molecule that activates protein kinase C (PKC), which plays an important role in learning, memory, and maintaining the health of synapses — the places where neurons (nerve cells) come into contact with, and send signals to, each other.

Key Accomplishments of Clinical Development Plan:

- Bryostatin demonstrated a favorable safety profile across both completed Phase II Pilot Alzheimer's disease trials
- Current trial has reported no safety issues to date
- Drug has been safely administered in over 1,600 patients
- Cognitive improvement over baseline, not just a slowing of the rate of decline
- Effect is persistent at least one month after dosing



Leadership

Alan Tuchman, M.D., Chief Executive Officer

Clinical Professor of Neurology at New York Medical College, in private practice of neurology in Manhattan; former chief medical officer of Oncolytic Biotech Inc.

Daniel Alkon, M.D., President and Chief Scientific Officer

30 years directing programs on the molecular and structural basis of associative memory at the National Neurologic Institute of NIH; founding scientific director of the Blanchette Rockefeller Neuroscience Institute.

Robert Weinstein, Chief Financial Officer

30 years, as an investment banker, healthcare private equity fund principal, chief financial officer, and public accountant.

Joshua Silverman, Chairman

Co-founder and managing member of Parkfield Funding LLC; former principal and managing partner of Iroquois Capital Management.

Market Snapshot

Share Price	52-Wk. Range	Avg. Vol.	Shares O/S	Market Cap
\$8.65 (1/18/22)	\$4.40 - \$14.50	100K	6.67M	\$57.7M

Synaptogenix, Inc. | 1185 Avenue of the Americas, 3rd Floor New York, NY 10036 | www.synaptogenix.com

Investor Relations Contact | 800-811-5591 | ir@synaptogenix.com

¹ *Fortune Business Insights*

² Scheff SW, Price DA. Alzheimer's disease-related alterations in synaptic density: neocortex and hippocampus. *J Alzheimers Dis.* 2006;9 (3 Suppl): 101-15.
Price and volume quotes from Yahoo! Finance

FORWARD-LOOKING STATEMENTS: This fact sheet contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this fact sheet regarding strategy, future operations, future financial position, future prospects, plans and objectives of management are forward-looking statements. Examples of forward-looking statements include, but are not limited to, the approach we are taking to discover and develop therapeutics for patients with life altering neurodegenerative diseases and developmental disorders; statements regarding Phase 2 study and further studies, and continued development of use of Bryostatin-1 for Alzheimer's Disease and other cognitive diseases; the expected timing of our anticipated clinical trial initiations and availability of clinical data; our ability to successfully initiate and complete clinical trials; and the difficulty in predicting the time and cost of development of our product candidates. There can be no assurance that the clinical program for Bryostatin-1 will be successful in demonstrating safety and/or efficacy, that we will not encounter problems or delays in clinical development, or that Bryostatin-1 will ever receive regulatory approval or be successfully commercialized. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: continued business impact from the COVID-19 global pandemic; weakening of economic conditions; legislative and regulatory actions; our inability to obtain adequate financing; the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity; our patent portfolio; our inability to expand our business; significant government regulation of pharmaceuticals and the healthcare industry; lack of product diversification; availability of our raw materials; existing or increased competition; stock volatility and illiquidity; and our failure to implement our business plans or strategies. You should not place undue reliance on these forward-looking statements. Additional information concerning these and other factors is contained in our filings with the U.S. Securities and Exchange Commission. These forward-looking statements are made based upon our current expectations and we undertake no duty to update them or any of the information contained in this fact sheet.